ROIV Roivant Sciences Ltd.
Nasdaq · SEC CIK 1635088 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $897.02M 47 sales by 12 insiders
- Filings on record
- 427 since 2021-10-22, latest 2026-09-22 21:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| MANCHESTER KEITH S | Dir | — | $154.47M |
| Gold Daniel Allen | Dir | — | $147.38M |
| QVT Financial LP | Dir by Deputization | — | $147.38M |
| Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| Ramaswamy Vivek | 10% | — | $105.88M |
| Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| Torti Frank | Pres, Vant COB | — | $82.04M |
| Gline Matthew | CEO, Dir | — | $46.17M |
| Pulik Richard | CFO | — | $9.12M |
| Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 563
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-05 | 2023-01-03 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +2,447 | 59.8K | +4% | $0 | |
| 2023-01-05 | 2023-01-03 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +2,010 | 60.2K | +3% | $0 | |
| M | 2023-01-04 | 2022-12-30+ | ROIV | Venker Eric | Pres, COO | S - Sale | $7.46 | -119.2K | 753.5K | -14% | -$889.0K |
| 2022-12-28 | 2022-12-23 | ROIV | Gline Matthew | CEO, Dir | J - Other | $7.10 | -19.4K | 1.13M | -2% | -$137.8K | |
| 2022-12-28 | 2022-12-23 | ROIV | Kumar Rakhi | CAO | J - Other | $7.10 | -1,592 | 136.2K | -1% | -$11.3K | |
| 2022-12-28 | 2022-12-23 | ROIV | Venker Eric | Pres, COO | J - Other | $7.10 | -16.0K | 901.6K | -2% | -$113.8K | |
| M | 2022-12-09 | 2022-12-08+ | ROIV | Venker Eric | Pres, COO | S - Sale | $7.03 | -145.1K | 888.7K | -14% | -$1.02M |
| 2022-11-22 | 2022-11-20 | ROIV | Gline Matthew | CEO, Dir | J - Other | $5.00 | -19.4K | 1.14M | -2% | -$96.9K | |
| 2022-11-22 | 2022-11-20 | ROIV | Venker Eric | Pres, COO | J - Other | $5.00 | -16.0K | 1.03M | -2% | -$80.0K | |
| 2022-11-22 | 2022-11-20 | ROIV | Kumar Rakhi | CAO | J - Other | $5.00 | -1,584 | 137.8K | -1% | -$7,920 | |
| I | 2022-11-15 | 2022-11-10 | ROIV | SVF Investments (UK) Ltd | 10% | S - Sale | $4.75 | -4.34M | 95.03M | -4% | -$20.63M |
| 2022-11-14 | 2022-11-10 | ROIV | Oren Dan | 10% | P - Purchase | $5.00 | +4.00M | 102.85M | +4% | +$20.00M | |
| MI | 2022-11-14 | 2022-11-10 | ROIV | QVT Financial LP | Dir, 10%, Dir by Deputization | S - Sale | $4.75 | -5.66M | 5.47M | -51% | -$26.87M |
| I | 2022-11-14 | 2022-11-09 | ROIV | QVT Financial LP | Dir, 10%, Dir by Deputization | J - Other | — | -1.20M | 38.58M | -3% | — |
| MI | 2022-11-14 | 2022-11-10 | ROIV | MANCHESTER KEITH S | Dir | S - Sale | $4.75 | -3.92M | 37.49M | -9% | -$18.63M |
| I | 2022-11-14 | 2022-11-09 | ROIV | MANCHESTER KEITH S | Dir | J - Other | — | -1.20M | 38.58M | -3% | — |
| 2022-11-14 | 2022-11-10 | ROIV | Gold Daniel Allen | Dir | G - Gift | — | -750.0K | 52.1K | -93% | — | |
| MI | 2022-11-14 | 2022-11-10 | ROIV | Gold Daniel Allen | Dir | S - Sale | $4.75 | -5.66M | 37.49M | -13% | -$26.87M |
| I | 2022-11-14 | 2022-11-09 | ROIV | Gold Daniel Allen | Dir | J - Other | — | -1.20M | 38.58M | -3% | — |
| 2022-11-02 | 2022-10-31 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +3,404 | 57.3K | +6% | $0 | |
| 2022-11-02 | 2022-10-31 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +2,796 | 58.2K | +5% | $0 | |
| 2022-10-27 | 2022-10-25 | ROIV | Kumar Rakhi | CAO | S - Sale | $4.40 | -1,588 | 139.4K | -1% | -$6,987 | |
| 2022-10-27 | 2022-10-25 | ROIV | Venker Eric | Pres, COO | S - Sale | $4.40 | -15.9K | 1.05M | -1% | -$70.1K | |
| 2022-10-27 | 2022-10-25 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $4.40 | -19.3K | 1.16M | -2% | -$84.8K | |
| 2022-09-27 | 2022-09-23 | ROIV | Kumar Rakhi | CAO | S - Sale | $3.07 | -1,741 | 140.9K | -1% | -$5,345 | |
| 2022-09-27 | 2022-09-23 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $3.07 | -21.1K | 1.18M | -2% | -$64.6K | |
| 2022-09-27 | 2022-09-23 | ROIV | Venker Eric | Pres, COO | S - Sale | $3.07 | -17.4K | 1.07M | -2% | -$53.4K | |
| D | 2022-09-19 | 2022-09-15 | ROIV | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +52.1K | 52.1K | New | $0 |
| D | 2022-09-19 | 2022-09-15 | ROIV | Lo Andrew | Dir | A - Grant | $0.00 | +52.1K | 52.1K | New | $0 |
| D | 2022-09-19 | 2022-09-15 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +50.0K | 53.9K | +1,275% | $0 |
| D | 2022-09-19 | 2022-09-15 | ROIV | Gold Daniel Allen | Dir | A - Grant | $0.00 | +52.1K | 52.1K | New | $0 |
| D | 2022-09-19 | 2022-09-15 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +52.1K | 55.4K | +1,618% | $0 |
| 2022-08-26 | 2022-08-24 | ROIV | Venker Eric | Pres, COO | S - Sale | $3.71 | -16.5K | 1.08M | -2% | -$61.3K | |
| 2022-08-26 | 2022-08-24 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $3.71 | -20.0K | 1.20M | -2% | -$74.2K | |
| 2022-08-26 | 2022-08-24 | ROIV | Kumar Rakhi | CAO | S - Sale | $3.71 | -1,652 | 142.7K | -1% | -$6,129 | |
| 2022-07-27 | 2022-07-25 | ROIV | Venker Eric | Pres, COO | S - Sale | $4.33 | -16.9K | 1.10M | -2% | -$73.2K | |
| 2022-07-27 | 2022-07-25 | ROIV | Kumar Rakhi | CAO | S - Sale | $4.33 | -1,686 | 144.3K | -1% | -$7,300 | |
| 2022-07-27 | 2022-07-25 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $4.33 | -20.5K | 1.22M | -2% | -$88.6K | |
| 2022-07-25 | 2022-07-20 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +3,923 | 3,923 | New | $0 | |
| 2022-07-25 | 2022-07-20 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +3,223 | 3,223 | New | $0 | |
| 2022-06-27 | 2022-06-23 | ROIV | Kumar Rakhi | CAO | S - Sale | $4.34 | -1,635 | 146.0K | -1% | -$7,096 | |
| 2022-06-27 | 2022-06-23 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $4.34 | -19.9K | 1.24M | -2% | -$86.2K | |
| 2022-06-27 | 2022-06-23 | ROIV | Venker Eric | Pres, COO | S - Sale | $4.34 | -16.4K | 1.12M | -1% | -$71.2K | |
| 2022-05-24 | 2022-05-20 | ROIV | Venker Eric | Pres, COO | S - Sale | $3.70 | -136.4K | 1.13M | -11% | -$504.8K | |
| 2022-05-24 | 2022-05-20 | ROIV | Kumar Rakhi | CAO | S - Sale | $3.70 | -12.1K | 147.7K | -8% | -$44.9K | |
| 2022-05-24 | 2022-05-20 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $3.70 | -139.8K | 1.26M | -10% | -$517.2K | |
| 2022-04-27 | 2022-04-25 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $3.84 | -8,509 | 1.40M | -0.6% | -$32.7K | |
| 2022-04-27 | 2022-04-25 | ROIV | Kumar Rakhi | CAO | S - Sale | $3.84 | -703 | 159.8K | -0.4% | -$2,700 | |
| 2022-04-27 | 2022-04-25 | ROIV | Venker Eric | Pres, COO | S - Sale | $3.84 | -5,107 | 1.27M | -0.4% | -$19.6K | |
| M | 2022-04-26 | 2022-04-22+ | ROIV | Dexcel Pharma Technologies Ltd. | 10% | P - Purchase | $3.85 | +40.3K | 98.85M | +0.0% | +$155.0K |
| 2022-04-01 | 2022-03-30 | ROIV | Venker Eric | Pres, COO | F - Tax | $4.74 | -15.1K | 1.27M | -1% | -$71.5K | |
| 2022-04-01 | 2022-03-30 | ROIV | Venker Eric | Pres, COO | S - Sale | $4.84 | -19.3K | 1.29M | -1% | -$93.6K | |
| 2022-04-01 | 2022-03-30 | ROIV | Kumar Rakhi | CAO | F - Tax | $4.74 | -2,077 | 160.5K | -1% | -$9,845 | |
| 2022-04-01 | 2022-03-30 | ROIV | Kumar Rakhi | CAO | S - Sale | $4.84 | -2,486 | 162.6K | -2% | -$12.0K | |
| 2022-04-01 | 2022-03-30 | ROIV | Gline Matthew | CEO, Dir | F - Tax | $4.74 | -25.3K | 1.41M | -2% | -$119.7K | |
| 2022-04-01 | 2022-03-30 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $4.84 | -33.7K | 1.44M | -2% | -$163.0K | |
| 2022-03-29 | 2022-03-25 | ROIV | Venker Eric | Pres, COO | S - Sale | $5.06 | -80.0K | 1.31M | -6% | -$405.0K | |
| 2022-03-29 | 2022-03-25 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $5.06 | -35.4K | 1.47M | -2% | -$179.1K | |
| 2022-03-29 | 2022-03-25 | ROIV | Kumar Rakhi | CAO | S - Sale | $5.06 | -7,281 | 165.0K | -4% | -$36.8K | |
| 2022-03-22 | 2022-03-18 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $5.13 | -82.0K | 1.51M | -5% | -$420.7K | |
| 2022-03-22 | 2022-03-18 | ROIV | Kumar Rakhi | CAO | S - Sale | $5.13 | -2,153 | 172.3K | -1% | -$11.0K | |
| 2022-03-09 | 2022-03-07 | ROIV | Kumar Rakhi | CAO | S - Sale | $5.52 | -3,091 | 174.5K | -2% | -$17.1K | |
| 2022-03-09 | 2022-03-07 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $5.52 | -92.3K | 1.59M | -5% | -$509.6K |
Purchase Sale Sale after option exercise All abbreviations